Centrient Pharmaceuticals on Monday started operation at its new dedicated manufacturing unit at Toansa in Punjab with an objective to scale up production capacity of statins in India.
“With doubling of our production capacity, we demonstrate our commitment to maintain our leadership position in line with our strategy and to continue supporting our customers’ business growth. Guided by our brand promise of Quality, Reliability and Sustainability, Centrient’s Rosuvastatin and Atorvastatin offer superior performance in all three areas to benefit of our customers and the environment,” said Frans Vlaar, the Chief Commercial Officer at Centrient.
Statins are currently the most prescribed drug class globally for the treatment of high cholesterol and cardiovascular diseases and are among the top-selling drugs worldwide.
Explore the profound effects of excessive screen time on your child’s behavior and development. Discover…
Discover how simple daily changes in your diet and lifestyle can significantly improve your heart…
This article explores the common misconception that brain tumours primarily affect older adults, revealing the…
The first-ever ovarian cancer vaccine is poised to change the landscape of women's health by…
As dengue and chikungunya cases rise in Delhi during the monsoon season, understanding prevention strategies…
Skincare is a significant concern for women (and increasingly, men), with the quest for perfect,…